Summary of Study ST001451
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000997. The data can be accessed directly via it's Project DOI: 10.21228/M8TH75 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST001451 |
| Study Title | Eleostearic acid effects on TAGs and oxLipids |
| Study Summary | Quantification of lipid species from cultured human MDA-MB-231 and BT549 cells with or without siRNA knockdown of ACSL1 and treated or not with eleostearic acid |
| Institute | Fox Chase Cancer Center |
| Last Name | Peterson |
| First Name | Jeffrey |
| Address | 333 Cottman Avenue Philadelphia, PA 19111 |
| Jeffrey.peterson@fccc.edu | |
| Phone | 215-728-3568 |
| Submit Date | 2020-08-20 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | raw(Thermo) |
| Analysis Type Detail | LC-MS |
| Release Date | 2020-09-10 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR000997 |
| Project DOI: | doi: 10.21228/M8TH75 |
| Project Title: | ACSL1 role in conjugated PUFA metabolism |
| Project Type: | MS quantitative lipidomic study |
| Project Summary: | Ferroptosis is associated with lipid hydroperoxides generated by oxidation of polyunsaturated acyl chains. Lipid hydroperoxides are reduced by glutathione peroxidase 4 (GPX4) and GPX4 inhibitors induce ferroptosis. However, the therapeutic potential of triggering ferroptosis in cancer cells with polyunsaturated fatty acids is unknown. We identified conjugated linoleates including α-eleostearate (αESA) as novel ferroptosis inducers. αESA did not alter GPX4 activity but was incorporated into cellular lipids and promoted lipid peroxidation and cell death in diverse cancer cell types. αESA-triggered death was mediated by acyl-CoA synthetase long-chain isoform 1, which promoted αESA incorporation into neutral lipids including triacylglycerols. Interfering with triacylglycerol biosynthesis suppressed ferroptosis triggered by αESA. |
| Institute: | Fox Chase Cancer Center |
| Last Name: | Peterson |
| First Name: | Jeffrey |
| Address: | 333 Cottman Avenue, Philadelphia, PA, 19111, USA |
| Email: | Jeffrey.peterson@fccc.edu |
| Phone: | 215-728-3568 |
| Funding Source: | DOD, NIH |
| Publications: | in process |
| Contributors: | Valarian Kagan |
Subject:
| Subject ID: | SU001525 |
| Subject Type: | Cultured cells |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Gender: | Female |
Factors:
Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)
| mb_sample_id | local_sample_id | siRNA |
|---|---|---|
| SA124011 | Nov5_2018_036 | ACSL1 | Treatment (8hrs):eleostearic acid (25µM) |
| SA124012 | Nov5_2018_037 | ACSL1 | Treatment (8hrs):eleostearic acid (25µM) |
| SA124013 | Jun17_2020_071 | ACSL1 | Treatment (8hrs):eleostearic acid (25µM) |
| SA124014 | Jun17_2020_073 | ACSL1 | Treatment (8hrs):eleostearic acid (25µM) |
| SA124015 | Nov5_2018_035 | ACSL1 | Treatment (8hrs):eleostearic acid (25µM) |
| SA124016 | Jun17_2020_069 | ACSL1 | Treatment (8hrs):eleostearic acid (25µM) |
| SA124017 | Nov5_2018_033 | ACSL1 | Treatment (8hrs):eleostearic acid (25µM) |
| SA124018 | Jun17_2020_063 | ACSL1 | Treatment (8hrs):eleostearic acid (25µM) |
| SA124019 | Nov5_2018_034 | ACSL1 | Treatment (8hrs):eleostearic acid (25µM) |
| SA124020 | Jun17_2020_065 | ACSL1 | Treatment (8hrs):eleostearic acid (25µM) |
| SA124021 | Jun17_2020_067 | ACSL1 | Treatment (8hrs):eleostearic acid (25µM) |
| SA124022 | Nov5_2018_032 | ACSL1 | Treatment (8hrs):eleostearic acid (25µM) |
| SA123999 | Nov5_2018_029 | ACSL1 | Treatment (8hrs):Vehicle (methanol) |
| SA124000 | Nov5_2018_027 | ACSL1 | Treatment (8hrs):Vehicle (methanol) |
| SA124001 | Nov5_2018_026 | ACSL1 | Treatment (8hrs):Vehicle (methanol) |
| SA124002 | Nov5_2018_030 | ACSL1 | Treatment (8hrs):Vehicle (methanol) |
| SA124003 | Jun17_2020_055 | ACSL1 | Treatment (8hrs):Vehicle (methanol) |
| SA124004 | Jun17_2020_051 | ACSL1 | Treatment (8hrs):Vehicle (methanol) |
| SA124005 | Jun17_2020_053 | ACSL1 | Treatment (8hrs):Vehicle (methanol) |
| SA124006 | Jun17_2020_057 | ACSL1 | Treatment (8hrs):Vehicle (methanol) |
| SA124007 | Nov5_2018_031 | ACSL1 | Treatment (8hrs):Vehicle (methanol) |
| SA124008 | Nov5_2018_028 | ACSL1 | Treatment (8hrs):Vehicle (methanol) |
| SA124009 | Jun17_2020_059 | ACSL1 | Treatment (8hrs):Vehicle (methanol) |
| SA124010 | Jun17_2020_061 | ACSL1 | Treatment (8hrs):Vehicle (methanol) |
| SA124035 | Jun17_2020_045 | Control | Treatment (8hrs):eleostearic acid (25µM) |
| SA124036 | Jun17_2020_043 | Control | Treatment (8hrs):eleostearic acid (25µM) |
| SA124037 | Jun17_2020_041 | Control | Treatment (8hrs):eleostearic acid (25µM) |
| SA124038 | Jun17_2020_039 | Control | Treatment (8hrs):eleostearic acid (25µM) |
| SA124039 | Jun17_2020_047 | Control | Treatment (8hrs):eleostearic acid (25µM) |
| SA124040 | Nov5_2018_022 | Control | Treatment (8hrs):eleostearic acid (25µM) |
| SA124041 | Jun17_2020_049 | Control | Treatment (8hrs):eleostearic acid (25µM) |
| SA124042 | Nov5_2018_025 | Control | Treatment (8hrs):eleostearic acid (25µM) |
| SA124043 | Nov5_2018_024 | Control | Treatment (8hrs):eleostearic acid (25µM) |
| SA124044 | Nov5_2018_023 | Control | Treatment (8hrs):eleostearic acid (25µM) |
| SA124045 | Nov5_2018_021 | Control | Treatment (8hrs):eleostearic acid (25µM) |
| SA124023 | Jun17_2020_037 | Control | Treatment (8hrs):Vehicle (methanol) |
| SA124024 | Jun17_2020_035 | Control | Treatment (8hrs):Vehicle (methanol) |
| SA124025 | Jun17_2020_027 | Control | Treatment (8hrs):Vehicle (methanol) |
| SA124026 | Nov5_2018_020 | Control | Treatment (8hrs):Vehicle (methanol) |
| SA124027 | Jun17_2020_033 | Control | Treatment (8hrs):Vehicle (methanol) |
| SA124028 | Nov5_2018_019 | Control | Treatment (8hrs):Vehicle (methanol) |
| SA124029 | Nov5_2018_018 | Control | Treatment (8hrs):Vehicle (methanol) |
| SA124030 | Nov5_2018_016 | Control | Treatment (8hrs):Vehicle (methanol) |
| SA124031 | Nov5_2018_017 | Control | Treatment (8hrs):Vehicle (methanol) |
| SA124032 | Jun17_2020_029 | Control | Treatment (8hrs):Vehicle (methanol) |
| SA124033 | Nov5_2018_015 | Control | Treatment (8hrs):Vehicle (methanol) |
| SA124034 | Jun17_2020_031 | Control | Treatment (8hrs):Vehicle (methanol) |
| Showing results 1 to 47 of 47 |
Collection:
| Collection ID: | CO001520 |
| Collection Summary: | BT-549 cells were transfected with ACSL1 or non-targeting siRNA 72 hours prior to incubation with 25 uM alpha eleostearic acid or vehicle (methanol) for 8 hours. After 8 hours, cells (~4-6 x 106 per replicate) were trypsinized, collected, washed once with phosphate-buffered saline, and frozen in liquid nitrogen. |
| Sample Type: | Breast cancer cells |
| Storage Conditions: | -80℃ |
Treatment:
| Treatment ID: | TR001540 |
| Treatment Summary: | Cells were treated in complete culture medium with 25uM alpha eleostearic acid or methanol (vehicle control) for eight hours |
| Treatment Compound: | alpha eleostearic acid |
Sample Preparation:
| Sampleprep ID: | SP001533 |
| Sampleprep Summary: | Cells were re-suspended in 25 mM HEPES buffer (pH 7.4) containing 200 μM DTPA and sonicated. |
Combined analysis:
| Analysis ID | AN002425 | AN002426 |
|---|---|---|
| Analysis type | MS | MS |
| Chromatography type | Normal phase | Reversed phase |
| Chromatography system | Thermo Dionex Ultimate 3000 | Thermo Dionex Ultimate 3000 |
| Column | Phenomenex Luna Silica (150 x 2.0mm,3um) | Phenomenex Luna Silica (150 x 1.0mm,3um) |
| MS Type | ESI | ESI |
| MS instrument type | Orbitrap | Orbitrap |
| MS instrument name | Thermo Fusion Orbitrap | Thermo Q Exactive HF hybrid Orbitrap |
| Ion Mode | NEGATIVE | POSITIVE |
| Units | pmol/mg | pmol/umol |
Chromatography:
| Chromatography ID: | CH001782 |
| Chromatography Summary: | Phospholipid protocol |
| Instrument Name: | Thermo Dionex Ultimate 3000 |
| Column Name: | Phenomenex Luna Silica (150 x 2.0mm,3um) |
| Chromatography Type: | Normal phase |
| Chromatography ID: | CH001783 |
| Chromatography Summary: | Triacylglycerols |
| Instrument Name: | Thermo Dionex Ultimate 3000 |
| Column Name: | Phenomenex Luna Silica (150 x 1.0mm,3um) |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS002262 |
| Analysis ID: | AN002425 |
| Instrument Name: | Thermo Fusion Orbitrap |
| Instrument Type: | Orbitrap |
| MS Type: | ESI |
| MS Comments: | Analysis of LC/MS data was performed using software package Compound Discoverer (ThermoFisher Scientific) with an in-house generated analysis workflow and oxidized phospholipid database. |
| Ion Mode: | NEGATIVE |
| MS ID: | MS002263 |
| Analysis ID: | AN002426 |
| Instrument Name: | Thermo Q Exactive HF hybrid Orbitrap |
| Instrument Type: | Orbitrap |
| MS Type: | ESI |
| MS Comments: | TAG cations were formed through molecular ammonium adduction (+NH4). Analysis was performed at a resolution of 140,000 for the full MS scan and 17,500 for the MS2 scan in a data-dependent mode. The scan range for MS analysis was 300–1200 m/z with a maximum injection time of 128 ms using one microscan. A maximum injection time of 500 ms was used for MS2 (high energy collisional dissociation (HCD)) analysis with collision energy set to 24. An isolation window of 1.0 Da was set for the MS and MS2 scans. Capillary spray voltage was set at 4.5 kV, and capillary temperature was 320 °C. Sheath gas was set to eight arbitrary units and the S-lens Rf level was set to 60. Standards for TAGs and their oxygenated metabolites were from Avanti Polar Lipids and Cayman Chemicals. |
| Ion Mode: | POSITIVE |
